Search - tctmd.com

Displaying 101 - 120 of 1381

Sort: Relevancy | Date

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Industry News

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

May 29, 2024

News Conference News EuroPCR 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

Shelley Wood

May 16, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

L.A. McKeown

May 03, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

Caitlin E. Cox

March 27, 2024

News Conference News CRT 2024

SAFE-MCS: Monitoring System Intercepts Bleeding in High-risk PCI

L.A. McKeown

March 15, 2024

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

Todd Neale

February 26, 2024

Advertisement

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

DCB in STEMI Match DES Through 5 Years: REVELATION

SAFE-MCS: Monitoring System Intercepts Bleeding in High-risk PCI

One in Three Overweight MI Patients May Benefit From Semaglutide

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content